Hengyu Medical Secures Nearly RMB 100 Million in Second Funding Round of the Year to Accelerate Integrated Vascular Intervention Platform

Dec 08, 2025 17:18 CST Updated 17:18

Horimed

OCT Imaging Equipment R&D and Manufacturer

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source: Yuansheng Ventures

Recently, Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed") announced the completion of nearly 100 million yuan in financing. This round of financing was jointly invested by Guanghua Wutong, Chengdu Sci-Tech Investment, and Zhongtian Weiyi. This is another significant financing completed by Horimed in 2025, which will help the company further accelerate the research and development, production, and commercialization process of vascular interventional endoluminal imaging and related therapeutic products.

Yuansheng Venture Capital invested in Horimed's D++ round of financing in February 2025.

Value Core: Building an Integrated Platform for Vascular Interventional Diagnosis and Treatment that is Scarce in China

The Appeal of Horimed Lies Not Only in Its Deep Cultivation of the Vascular Intervention Field, but Also in Its Commitment to Building a Complete Technical System and Irreplicable R&D Capabilities. After Years of Focus on Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) Technologies, Horimed Has Established an End-to-End Layout Covering Core Components to Complete Equipment, and from Single Products to System Solutions. Horimed is One of the Few Companies in China That Simultaneously Masters Both IVUS and OCT Core Technologies, Giving It a Unique Position in the Field of Precision Diagnosis and Treatment for Vascular Interventions Through This "Dual-Technology Approach." Furthermore, the Success of Its Single-Source Dual-Modality OCT-NIRS Technology, Which Integrates OCT with Near-Infrared Spectroscopy (NIRS), Has Enabled Horimed to Establish a Three-Modal Imaging Mode of OCT/IVUS/NIRS, Offering Clinicians a More Comprehensive Solution for Diagnosis and Treatment.

Market Opportunities: AI Empowers Smart Healthcare, the Era of Precision Medicine Has Arrived

With the deepening of the concept of precision medicine and the increasing demand for surgical standardization, the need for real-time, precise imaging navigation during vascular interventional procedures is growing rapidly. Artificial intelligence technology has demonstrated significant advantages in medical image analysis, surgical path planning, and real-time navigation. China has a large population of cardiovascular disease patients, and the number of coronary intervention surgeries performed annually continues to rise. However, the penetration rate of intravascular imaging technology still lags far behind that of developed countries, representing a huge market potential and growth opportunity. Meanwhile, as clinical guidelines increasingly recommend intraluminal imaging technology and the medical insurance payment policies gradually improve, China's intravascular imaging market is about to enter a period of rapid growth. Horimed, with its comprehensive product portfolio and technical expertise in AI-powered smart healthcare, has developed an integrated solution combining imaging acquisition, intelligent analysis, and surgical guidance, fully preparing itself for the boom in the AI precision medicine market.

Strategic Upgrade: Expanding from Cardiovascular to Pan-Vascular Ecosystem

Horimed is undergoing a strategic upgrade from being a "cardiovascular expert" to becoming a "pan-vascular platform." Behind this transformation lies Horimed's deep insight and forward-looking layout in the vascular disease diagnosis and treatment market. Based on thorough market analysis and technology evaluation, as well as its technical reserves in the cardiovascular field, Horimed has expanded its product pipelines to include cerebral vascular OCT, carotid artery OCT, peripheral vascular IVUS, 4D ICE, and laser ablation. Notably, the 4D ICE product offers more advantages over 2D ICE products in terms of operational difficulty, imaging field of view, and modeling quality.

This ecological expansion is due to Horimed's solid underlying technical foundation and the team's continuous self-iteration ability. The cross-field expansion of indications not only reduces the risk of technology development but also opens up broad development space for Horimed to further expand its business layout.

About Horimed

Horimed Technology Co., Ltd., established in 2016, focuses on the independent research, production, and sales of Intravascular Ultrasound (IVUS) equipment and catheters, Optical Coherence Tomography (OCT) equipment and catheters, IVUS/OCT integrated dual-catheter systems, Fractional Flow Reserve (FFR) platforms based on IVUS and OCT, single-source dual-modality OCT-NIRS technology that integrates OCT with Near-Infrared Spectroscopy (NIRS), and intravascular laser plaque ablation technology. The company has mastered optical, ultrasound, and catheter platform technologies and continues to innovate globally based on foundational technologies, striving to provide an integrated pan-vascular solution based on imaging products for medical professionals and patients.

END

13.4 Billion, Imaging Giant Plans IPO

Johnson & Johnson's Product Rejected Unanimously

For the First Time, China's National Healthcare Security Administration Proposes to Build a Price Framework for Surgical Robots and Remote Surgery

Orthopedic Leader Exits, Olympus Takes Over

Valued at 5.5 Billion, Innovative Medical Device Company Plans to Go Public

Medtronic + Abbott, New Ecosystem

Global Medical Device Giant Expands in China for the Second Time in a Year

Leader in China-produced surgical instruments, proposed IPO

"Legend CEO of 'King of Rigid Endoscopes' Passes Away"

Localization of Indigenous Technological Achievements: Fujifilm Advances the Development of Precise Endoscopic Diagnosis and Treatment

BusinessBusiness cooperation email: qxzj@landianyiliao.com